Temple is recruiting participants for third phase of Johnson & Johnson’s COVID-19 vaccine trial


PHILADELPHIA (KYW Newsradio) — The latest developments for a COVID-19 vaccine have been promising — AstraZeneca, Moderna and Pfizer all say their respective clinical trials have been highly effective.

Johnson & Johnson is working on its own vaccine, basing some of its research in Philadelphia.

Temple University Hospital is recruiting people for its third trial phase of Johnson & Johnson’s COVID-19 vaccine — 1,400 people from all across the city, who are 18 and older.

There is just one shot in this vaccine, but it is a lengthy commitment, including several in-person visits.

"There is a study portal,” said Dr. Nina Gentile, professor of emergency medicine, who is leading the trial at Temple, “and participants are asked to enter study data fairly regularly — at least twice a week for at least a year. Then, every couple of weeks for the following year.”

There is a stipend for travel expenses, meals and parking. Gentile said it’s important to have more than one vaccine approved, given the number of people who need to be protected during the pandemic and the logistics of shipping vaccines worldwide.

For more information or to see if you qualify for the trial, visit ensemblestudy.com.